[go: up one dir, main page]

TR200003108T2 - İlaç kompozisyonları - Google Patents

İlaç kompozisyonları

Info

Publication number
TR200003108T2
TR200003108T2 TR2000/03108T TR200003108T TR200003108T2 TR 200003108 T2 TR200003108 T2 TR 200003108T2 TR 2000/03108 T TR2000/03108 T TR 2000/03108T TR 200003108 T TR200003108 T TR 200003108T TR 200003108 T2 TR200003108 T2 TR 200003108T2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
macrophate
melters
impregnants
thickeners
Prior art date
Application number
TR2000/03108T
Other languages
English (en)
Inventor
Ibuki Rinta
Shimojo Fumio
Ueda Satoshi
Toyoda Toshihiko
Yamanaka Masayuk�
Yoshida Erika
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of TR200003108T2 publication Critical patent/TR200003108T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Aktif madde olarak trisiklik bilesikler (I) tarafindan temsil edilen makrolit bilesiklerini içeren, yüksek bir kararliliga, mükemmel bir emilebilirlige ve/ ya da çok az tahris etme özelligine sahip olan ilaç kompozisyonlari ya da istege bagli olarak iyilestirici ajanlar ve/ya da kalinlastiricilarla uyumlu olan bunlarin farmasötik olarak uygun olan tuzlari, eriticileri, emdiricileri ve bazlari.
TR2000/03108T 1998-04-27 1999-04-26 İlaç kompozisyonları TR200003108T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11727198 1998-04-27

Publications (1)

Publication Number Publication Date
TR200003108T2 true TR200003108T2 (tr) 2001-02-21

Family

ID=14707636

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03108T TR200003108T2 (tr) 1998-04-27 1999-04-26 İlaç kompozisyonları

Country Status (24)

Country Link
US (2) US6673808B1 (tr)
EP (1) EP1074255B1 (tr)
JP (1) JP3732525B2 (tr)
KR (1) KR100406823B1 (tr)
CN (1) CN1161117C (tr)
AR (1) AR018330A1 (tr)
AT (1) ATE363275T1 (tr)
AU (1) AU749475B2 (tr)
BR (1) BR9910336A (tr)
CA (1) CA2326222C (tr)
DE (1) DE69936195T2 (tr)
ES (1) ES2284248T3 (tr)
HK (1) HK1038884B (tr)
HU (1) HUP0104452A3 (tr)
ID (1) ID29262A (tr)
IL (1) IL139210A (tr)
NO (1) NO20005399L (tr)
NZ (1) NZ507345A (tr)
PL (1) PL343627A1 (tr)
RU (1) RU2203058C2 (tr)
TR (1) TR200003108T2 (tr)
TW (1) TW565461B (tr)
WO (1) WO1999055332A1 (tr)
ZA (1) ZA200005378B (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
JP5036934B2 (ja) * 1999-04-30 2012-09-26 ラスク・インテレクチュアル・リザーブ・アクチェンゲゼルシャフト ドライアイ処置の為のマクロライド化合物の使用
DK3351246T3 (da) * 2001-02-19 2019-06-03 Novartis Pharma Ag Rapamycinderivat til behandling af en solid tumor, som er associeret med dereguleret angionese
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
WO2006001251A1 (ja) * 2004-06-24 2006-01-05 Kowa Co., Ltd. アトルバスタチン外用剤組成物
KR101453963B1 (ko) 2005-03-03 2014-10-22 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
CN101163474B (zh) * 2005-04-21 2012-02-22 参天制药株式会社 角膜结膜病变治疗剂
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
CN102176913B (zh) * 2008-10-08 2014-08-13 高田制药株式会社 外用的他克莫司制剂
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
JP2011102260A (ja) * 2009-11-11 2011-05-26 Takada Seiyaku Kk タクロリムス外用剤
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
AU2012211809A1 (en) * 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same
JPWO2021149827A1 (tr) * 2020-01-24 2021-07-29

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454113A (en) * 1982-09-21 1984-06-12 Scm Corporation Stabilization of oil and water emulsions using polyglycerol esters of fatty acids
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
JPH05505798A (ja) * 1990-03-13 1993-08-26 フアイソンズ・ピーエルシー 免疫抑制マクロ環状化合物
EP0533930A1 (en) * 1990-06-11 1993-03-31 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
SG46547A1 (en) * 1990-09-04 1998-02-20 Fujisawa Pharmaceutical Co Ointments containing tricyclic compounds
EP0480623A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
TW213418B (tr) * 1991-05-02 1993-09-21 Kuko Seiyaku Kk
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
JPH06128148A (ja) * 1992-04-30 1994-05-10 Dotsuto:Kk 皮膚外用剤
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
JP2523428B2 (ja) * 1992-12-04 1996-08-07 エスエス製薬株式会社 消炎鎮痛ゲル製剤
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
DE69525957T2 (de) * 1994-10-26 2002-11-14 Novartis Ag Verwendung eines ungesättigten Fettalkohols
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
AU705320B2 (en) * 1995-12-28 1999-05-20 Welfide Corporation 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof for use in the preparation of a non-oral medicament, and for treatment of diseases and disorders
CZ267796A3 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
WO1998046268A1 (fr) * 1997-04-11 1998-10-22 Fujisawa Pharmaceutical Co., Ltd. Composition medicamenteuse

Also Published As

Publication number Publication date
NZ507345A (en) 2002-12-20
KR100406823B1 (ko) 2003-11-21
AU3537299A (en) 1999-11-16
ID29262A (id) 2001-08-16
EP1074255A4 (en) 2002-02-13
US6673808B1 (en) 2004-01-06
WO1999055332A1 (fr) 1999-11-04
WO1999055332A8 (fr) 2000-02-17
HK1038884A1 (en) 2002-04-04
TW565461B (en) 2003-12-11
NO20005399D0 (no) 2000-10-26
CN1307475A (zh) 2001-08-08
PL343627A1 (en) 2001-08-27
RU2203058C2 (ru) 2003-04-27
KR20010042589A (ko) 2001-05-25
JP3732525B2 (ja) 2006-01-05
US6586444B2 (en) 2003-07-01
IL139210A (en) 2005-11-20
DE69936195D1 (de) 2007-07-12
HUP0104452A3 (en) 2004-05-28
CN1161117C (zh) 2004-08-11
EP1074255A1 (en) 2001-02-07
AU749475B2 (en) 2002-06-27
AR018330A1 (es) 2001-11-14
CA2326222C (en) 2008-09-23
ZA200005378B (en) 2002-08-23
US20020061907A1 (en) 2002-05-23
ES2284248T3 (es) 2007-11-01
CA2326222A1 (en) 1999-11-04
HUP0104452A2 (hu) 2002-03-28
IL139210A0 (en) 2001-11-25
HK1038884B (zh) 2005-05-06
BR9910336A (pt) 2001-09-25
ATE363275T1 (de) 2007-06-15
NO20005399L (no) 2000-10-26
EP1074255B1 (en) 2007-05-30
DE69936195T2 (de) 2007-09-13

Similar Documents

Publication Publication Date Title
TR200003108T2 (tr) İlaç kompozisyonları
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
DK1157037T3 (da) GCSF-konjugater
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
MX9700885A (es) Nuevas heteroariloxazolidinonas.
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
IL140710A0 (en) Pulmonary delivery of active agents
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
SE9900961D0 (sv) Novel compounds
BR0007589A (pt) Inibidores da proliferação de células
SE9802208D0 (sv) Novel compounds
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
DK1056771T3 (da) Streptograminderivater, deres fremstilling og præparater, der indeholder dem
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
SE9802209D0 (sv) Novel compounds
TR199700735T1 (tr) Istege göre azt,DD1 ya da DDC ile birlikte ters transkritaz inhibitörü 3T ve HIV proteaz inhibitörü indinavirin kullanilmasiyla HIV enfeksiyoun için bir arada terapi.
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
SE9504662D0 (sv) New compounds
DE69727583D1 (de) Vermeidung von gastrointestinaler schädigung
UY26498A1 (es) Pirroles sustituidos